THERAGEN ETEX CO.,LTD. Logo

THERAGEN ETEX CO.,LTD.

A biotech firm offering gene analysis and developing personalized cancer drugs.

066700 | KO

Overview

Corporate Details

ISIN(s):
KR7066700006
LEI:
Country:
South Korea
Address:
경기도 안산시 단원구 산단로 68번길 58(초지동), 안산시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

THERAGEN ETEX CO., LTD. is a biotechnology and pharmaceutical company specializing in genome-based personalized and precision medicine. The company integrates two core capabilities: advanced gene analysis and pharmaceutical development. Its genomics division provides high-level genome sequencing and analysis services, having achieved milestones such as creating the world's first female and tiger genome maps. The pharmaceutical division operates international GMP-certified facilities to manufacture and supply medicines. It focuses on developing a new drug pipeline that includes incrementally modified drugs, orphan drugs, and novel anticancer treatments. A key candidate, Vactosertib, is currently undergoing clinical trials in Korea and the U.S. for various cancers. This synergistic approach positions the company at the forefront of personalized healthcare solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-30 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.3 KB
2025-07-30 00:00
Management Discussion and Analysis
영업실적등에대한전망(공정공시)
Korean 10.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-05-08 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.1 KB
2025-05-08 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.9 KB
2025-05-08 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.4 KB
2025-04-30 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-04-22 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-04-18 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-04-10 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 94.8 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 19.8 KB
2025-03-24 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 40.7 KB
2025-03-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 99.7 KB
2025-03-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.7 KB

Automate Your Workflow. Get a real-time feed of all THERAGEN ETEX CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for THERAGEN ETEX CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for THERAGEN ETEX CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.